Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15872041 | 0.90 | HRH3 (0.54) | ALDH1A1HRH3KDM4ETDP1GAA | |
| SCHEMBL3352630 | 0.88 | HRH3 (0.58) | ALDH1A1HRH3KDM4ETDP1GAA | |
| SCHEMBL18775271 | 0.86 | LMNA (0.59) | ALDH1A1TSHRKDM4EPRMT6NCF1 | |
| SCHEMBL24197405 | 0.84 | MAPT (0.49) | ALDH1A1HRH3NCF1BRD4 | |
| SCHEMBL30417083 | 0.84 | MAPT (0.49) | ALDH1A1HRH3NCF1BRD4 | |
| SCHEMBL19847092 | 0.80 | GPR183 (0.42) | ALDH1A1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL6295492 | 0.79 | HRH3 (0.55) | ALDH1A1HRH3KDM4EGAAMEN1 | |
| SCHEMBL13674757 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HRH3KDM4ETDP1GAA | |
| SCHEMBL15587428 | 0.78 | ALDH1A1 (0.54) | ALDH1A1HRH3KDM4ETDP1GAA | |
| SCHEMBL546248 | 0.77 | ALDH1A1 (0.51) | ALDH1A1HRH3TSHRKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885HRH3 252/4885TSHR 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.